Latest Health News

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.

Charter Hall Group has raised its FY26 operating earnings per security guidance by 5.5%, reflecting robust momentum in property investments and funds management. The upgrade signals growing investor confidence and increased transaction volumes across its platforms.

HomeCo Daily Needs REIT has announced a quarterly cash distribution of 2.15 cents per unit for Q3 2025, including a fund payment component under Australian tax law. The REIT confirms its tax structure intentions for the 2026 financial year.

Close the Loop Limited reports stronger Q1 FY26 revenue and EBITDA, boosted by strategic asset sales and operational improvements, while navigating key board and CFO departures.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

ReadCloud Limited reported a robust FY25 with a 109% surge in underlying EBITDA, driven by strong growth in its Australian school businesses. The company’s FY26 outlook targets continued organic expansion and disciplined execution amid industry funding uncertainties.

Cyprium Metals has secured board approval to restart copper cathode production at its Nifty Copper Complex, targeting first output by mid-2026. The plan leverages existing heap leach resources and refurbishes key processing infrastructure to generate near-term cash flow.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.

Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.

AXP Energy reports sustained strong flowback at its Charlie #1 well in Oklahoma, moving swiftly to install infrastructure for natural gas sales and early revenue generation.